Biopharmaceutical industry sees mixed performance in 2024: report

Over two-thirds of the top 20 global firms reported a decline in market capitalisation.

The biopharmaceutical industry showed a mixed performance in 2024, with the aggregate market capitalisation of the top 20 biopharmaceutical firms increasing by 1.7% to $3.7t as of 31 December.

According to GlobalData, over two-thirds of these companies reported a decline in market capitalisation.

“Three companies achieved growth greater than 10%: Lilly (32.4%), AbbVie (14.8%) and Gilead Sciences (14.0%),” the report said.

The industry’s performance reflected growing uncertainty due to shifting policies and regulatory concerns, said Ophelia Chan, Business Fundamentals Senior Analyst at GlobalData.

“With Trump’s second term raising concerns around drug pricing, inflation trends, and FDA approvals, the industry faces an unclear outlook heading into 2025,” Chan added.